Selina M. Sonntag
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Selina M. Sonntag has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Achim Theo Brinkop
Institute of Biophysics Ulm University 89081 Ulm Germany
2 shared publications Alina Thielen
Faculty of Physics and Center for NanoScience (CeNS) LMU 80539 Munich Germany
2 shared publications- Elijah Robinson Shelton
Faculty of Physics and Center for NanoScience (CeNS) LMU 80539 Munich Germany
2 shared publications - Friedhelm Serwane
Institute of Biophysics Ulm University 89081 Ulm Germany
2 shared publications Katja A. Salbaum
Faculty of Physics and Center for NanoScience (CeNS) LMU 80539 Munich Germany
2 shared publicationsRebecca James
Faculty of Physics and Center for NanoScience (CeNS) LMU 80539 Munich Germany
2 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 57, 430-444
Small patients – Big needs: A material-based approach to develop miniaturised valves for congenital heart diseases
Paediatric valve replacements cannot be built by simply scaling down bigger-sized valve implants. Innovative approaches that combine novel material systems, processing technologies, and device designs are needed to develop adaptable, durable, and biocompatible miniaturised solutions tailored to the paediatric population with congenital heart diseases. In response to that medical need, in this work, we have developed miniaturised valves following a biohybrid approach that combines synthetic components with bioinspired materials to exploit the optimal properties of each. Specifically, the valve was composed of (i) an electrospun synthetic polymer to provide stability, (ii) protein-engineered elastin to ensure flexibility and low thrombogenicity, and (iii) a tailor-made stent to enable minimally invasive implantation. Our valve implant demonstrated outstanding maximum strain values over 300 %, maximum stresses exceeding 6 MPa, and the ability to withstand burst pressures over 1000 mmHg. Blood compatibility tests revealed lower platelet activation than ePTFE, which is a material used in clinical applications. The hydrodynamics of the miniaturised valve met the standards outlined in the ISO guidelines with regurgitation fractions below 15 % and complete valve closure, indicating excellent functionality. Overall, we have established a material-based approach to address the clinical demand for small valves for children suffering from congenital heart diseases.
- 1 March 2026
- Published by KEAI Publishing in Bioactive Materials
- Vol. 57, 430-444
Open AccessSmall patients – Big needs: A material-based approach to develop miniaturised valves for congenital heart diseases
Paediatric valve replacements cannot be built by simply scaling down bigger-sized valve implants. Innovative approaches that combine novel material systems, processing technologies, and device designs are needed to develop adaptable, durable, and biocompatible miniaturised solutions tailored to the paediatric population with congenital heart diseases. In response to that medical need, in this work, we have developed miniaturised valves following a biohybrid approach that combines synthetic components with bioinspired materials to exploit the optimal properties of each. Specifically, the valve was composed of (i) an electrospun synthetic polymer to provide stability, (ii) protein-engineered elastin to ensure flexibility and low thrombogenicity, and (iii) a tailor-made stent to enable minimally invasive implantation. Our valve implant demonstrated outstanding maximum strain values over 300 %, maximum stresses exceeding 6 MPa, and the ability to withstand burst pressures over 1000 mmHg. Blood compatibility tests revealed lower platelet activation than ePTFE, which is a material used in clinical applications. The hydrodynamics of the miniaturised valve met the standards outlined in the ISO guidelines with regurgitation fractions below 15 % and complete valve closure, indicating excellent functionality. Overall, we have established a material-based approach to address the clinical demand for small valves for children suffering from congenital heart diseases.
- Open Access
- 12 June 2025
- Published by Wiley in Small Methods
- Vol. 10 (2) , e2401050
3D Quantification of Viral Transduction Efficiency in Living Human Retinal Organoids
The development of therapeutics builds on testing their efficiency in vitro. To optimize gene therapies, for example, fluorescent reporters expressed by treated cells are typically utilized as readouts. Traditionally, their global fluorescence signal has been used as an estimate of transduction efficiency. However, analysis in individual cells within a living 3D tissue remains a challenge. Readout on a single‐cell level can be realized via fluorescence‐based flow cytometry at the cost of tissue dissociation and loss of spatial information. Complementary, spatial information is accessible via immunofluorescence of fixed samples. Both approaches impede time‐dependent studies on the delivery of the vector to the cells. Here, quantitative 3D characterization of viral transduction efficiencies in living retinal organoids is introduced. The approach combines quantification of gene delivery efficiency in space and time, leveraging human retinal organoids, engineered adeno‐associated virus (AAV) vectors, confocal live imaging, and deep learning‐based image segmentation. The integration of these tools in an organoid imaging and analysis pipeline allows quantitative testing of future treatments and other gene delivery methods. It has the potential to guide the development of therapies in biomedical applications.
- 12 June 2025
- Published by Wiley in Small Methods
- Vol. 10 (2) , e2401050
Open Access3D Quantification of Viral Transduction Efficiency in Living Human Retinal Organoids
The development of therapeutics builds on testing their efficiency in vitro. To optimize gene therapies, for example, fluorescent reporters expressed by treated cells are typically utilized as readouts. Traditionally, their global fluorescence signal has been used as an estimate of transduction efficiency. However, analysis in individual cells within a living 3D tissue remains a challenge. Readout on a single‐cell level can be realized via fluorescence‐based flow cytometry at the cost of tissue dissociation and loss of spatial information. Complementary, spatial information is accessible via immunofluorescence of fixed samples. Both approaches impede time‐dependent studies on the delivery of the vector to the cells. Here, quantitative 3D characterization of viral transduction efficiencies in living retinal organoids is introduced. The approach combines quantification of gene delivery efficiency in space and time, leveraging human retinal organoids, engineered adeno‐associated virus (AAV) vectors, confocal live imaging, and deep learning‐based image segmentation. The integration of these tools in an organoid imaging and analysis pipeline allows quantitative testing of future treatments and other gene delivery methods. It has the potential to guide the development of therapies in biomedical applications.
- Open Access
3D Quantification of Viral Transduction Efficiency in Living Human Retinal Organoids
The development of therapeutics relies on testing their efficiency and specificity in animals and human in vitro models. To optimize the efficiency of a gene therapy, for example, fluorescent reporters expressed by treated cells are often utilized as readouts. Traditionally, the overall fluorescence signal provides an estimate for the global transduction efficiency. However, detailed analysis of the transduction efficiency in individual cells within a tissue remains a challenge. Readout on a single cell level can be realized via fluorescence-activated cell sorting at the cost of tissue dissociation into single cells and loss of spatial information. Complementary, spatial information is accessible via immunofluorescence characterization of fixed samples. However, those approaches impede time-dependent studies and prevent the recording of the dynamic interplay between the viral vector and the target cells in a 3D tissue. Here, we provide a quantitative, three-dimensional characterization of viral transduction efficiencies in living retinal organoids. We combine engineered adeno-associated virus (AAV) vectors, confocal live-imaging, and deep learning-based image segmentation to establish a quantitative test platform for gene delivery. To establish this, we transduced human retinal organoids with specific AAV vectors and imaged the fluorescent reporter expression in 3D. We measured a faster onset (7 days) and higher transduction efficiency (82%) of an AAV vector with optimized serotype (AAV2.NN) compared to two other AAV serotypes (AAV2.7m8, AAV9.NN). This highlights the practicality and functionality of our platform as a testbed for future treatments. The combination of optimized viral vectors, live-imaging, and deep learning-based image processing has the potential to guide the development of therapies in a variety of biomedical applications.
Open Access3D Quantification of Viral Transduction Efficiency in Living Human Retinal Organoids
The development of therapeutics relies on testing their efficiency and specificity in animals and human in vitro models. To optimize the efficiency of a gene therapy, for example, fluorescent reporters expressed by treated cells are often utilized as readouts. Traditionally, the overall fluorescence signal provides an estimate for the global transduction efficiency. However, detailed analysis of the transduction efficiency in individual cells within a tissue remains a challenge. Readout on a single cell level can be realized via fluorescence-activated cell sorting at the cost of tissue dissociation into single cells and loss of spatial information. Complementary, spatial information is accessible via immunofluorescence characterization of fixed samples. However, those approaches impede time-dependent studies and prevent the recording of the dynamic interplay between the viral vector and the target cells in a 3D tissue. Here, we provide a quantitative, three-dimensional characterization of viral transduction efficiencies in living retinal organoids. We combine engineered adeno-associated virus (AAV) vectors, confocal live-imaging, and deep learning-based image segmentation to establish a quantitative test platform for gene delivery. To establish this, we transduced human retinal organoids with specific AAV vectors and imaged the fluorescent reporter expression in 3D. We measured a faster onset (7 days) and higher transduction efficiency (82%) of an AAV vector with optimized serotype (AAV2.NN) compared to two other AAV serotypes (AAV2.7m8, AAV9.NN). This highlights the practicality and functionality of our platform as a testbed for future treatments. The combination of optimized viral vectors, live-imaging, and deep learning-based image processing has the potential to guide the development of therapies in a variety of biomedical applications.